A	O
common	O
human	O
skin	I-DiseaseClass
tumour	I-DiseaseClass
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs.	O
In	O
response	O
to	O
this	O
stimulus,	O
cytoplasmic	O
beta-catenin	O
(encoded	O
by	O
CTNNB1)	O
is	O
stabilized,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF/TCF	O
family.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin/TCF	O
encodes	O
c-MYC,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer,	I-DiseaseClass
particularly	O
in	O
the	O
colon.	O
Most	O
colon	I-DiseaseClass
cancers	I-DiseaseClass
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
(APC),	I-SpecificDisease
a	O
protein	O
required	O
for	O
ubiquitin-mediated	O
degradation	O
of	O
beta-catenin,	O
but	O
a	O
small	O
percentage	O
of	O
colon	I-CompositeMention
and	I-CompositeMention
some	I-CompositeMention
other	I-CompositeMention
cancers	I-CompositeMention
harbour	O
beta-catenin-stabilizing	O
mutations.	O
Recently,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	I-DiseaseClass
tumours	I-DiseaseClass
resembling	O
pilomatricomas.	I-SpecificDisease
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair-follicle	O
morphogenesis,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	I-SpecificDisease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin-stabilizing	O
mutations.	O
Here,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	I-DiseaseClass
tumour.	I-DiseaseClass
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	I-Modifier
cells,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	I-SpecificDisease
are	O
derived	O
from	O
hair	O
matrix	O
cells.	O
At	O
least	O
75%	O
of	O
these	O
tumours	I-DiseaseClass
possess	O
mutations	O
affecting	O
the	O
amino-terminal	O
segment,	O
normally	O
involved	O
in	O
phosphorylation-dependent,	O
ubiquitin-mediated	O
degradation	O
of	O
the	O
protein.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	I-DiseaseClass
examined	O
thus	O
far,	O
and	O
directly	O
implicates	O
beta-catenin/LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans..	O

HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	I-Modifier
probands:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis.	I-SpecificDisease
Hereditary	I-SpecificDisease
hemochromatosis	I-SpecificDisease
(HH)	I-SpecificDisease
is	O
a	O
common	O
autosomal	I-DiseaseClass
recessive	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
of	O
iron	O
metabolism.	O
The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I-like	O
protein	O
involved	O
in	O
HH	I-SpecificDisease
was	O
identified	O
in	O
1996.	O
Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y,	O
accounting	O
for	O
80%	O
to	O
90%	O
of	O
HH	I-Modifier
chromosomes,	O
and	O
H63D,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40%	O
to	O
70%	O
of	O
non-C282Y	O
HH	I-Modifier
chromosomes.	O
We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y,	O
H63D,	O
and	O
the	O
193A--	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	O
substitution	O
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls.	O
The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis,	I-SpecificDisease
accounting	O
for	O
85%	O
of	O
carrier	O
chromosomes,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39%	O
of	O
the	O
HH	I-Modifier
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation.	O
In	O
addition,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	O
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	O
an	O
assigned	O
mutation.	O
This	O
substitution	O
accounted	O
for	O
7.	O
8%	O
of	O
HH	I-Modifier
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D.	O
This	O
enrichment	O
of	O
S65C	O
among	O
HH	I-Modifier
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis.	I-SpecificDisease

